Previous SANS studies of anti-cancer polymer-drug conjugates (PDCs) (HPMA-Doxorubicin) identified a correlation between conjugate solution conformation and clinical results. The use of a non-biodegradable polymer, however, limits the molecular weight that is clinically viable, which can result in reduced drug loading capacity, circulation times, targeting capacity. As part of our study to correlate biological activity with PDC structure we have selected a dextrin as an appropriate biodegradable alternative to HPMA. Conjugates with aromatic drug mimics will be studied, under pseudo-biological conditions (T, pH, ionic strength), using contrast variation experiments to obtain a more detailed picture of conjugate solution conformation. These will be compared with HPMA conjugates to determine the influence of backbone structure, and how these impact on drug release rates.